medigraphic.com

2020, Number 1

<< Back

Rev Med Inst Mex Seguro Soc 2020; 58 (1)

Jejunal gastrointestinal stromal tumor (GIST): clinical case

Navarrete-Salazar VE, Fierro-Macías AE, Mena-Burciaga VM, Franco-Prieto CM, Gallardo-Loya AF, Martínez-Meraz M

Language: Spanish
References: 25
Page: 66-75
PDF size: 299.37 Kb.


ABSTRACT

Background: Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract. It is exposed a clinical case of jejunal GIST from a second-level hospital in Mexico.
Clinical case: Female patient of 76 years, with history of tobacco use (two cigarettes per day for 25 years), that is referred to General Surgery due to a four-month evolution of symptoms, characterized by abdominal pain, hyporexia and urinary symptomatology. Physical examination revealed a non-pulsatile, solid, non-mobile, non-painful mass in the hypogastrium and right iliac fossa of approximately 15 cm in length. Ovarian tumor was ruled out, since CEA and CA-125 tumor markers were negative. Abdominopelvic ultrasound was performed and reported a solid tumor with cystic spaces inside. CT reported a solid tumor of 9.5 x 2.5 x 8.3 cm, with defined edges, multilobed, presence of some calcifications in its wall that did not show enhancement with the use of contrast media. Patient underwent exploratory laparotomy and it was found a jejunal tumor, 210 cm from the ligament of Treitz. Immunohistochemistry reported positivity to KIT and DOG1, confirming the diagnosis of GIST.
Conclusion: GISTs are uncommon entities. Their clinical presentation is insidious and the preoperative diagnosis is complex due to the need for biopsy. The treatment is surgery, but tyrosine kinase inhibitors should be administered. Even in patients with response to treatment, follow-up is mandatory due to the risk of recurrence.


REFERENCES

  1. Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, et al. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8(2):S1-41.

  2. Poveda A, García Del Muro X, López-Guerrero JA, Cubedo R, Martínez V, Romero I, et al. GEIS guidelines for gastrointestinal sarcomas (GIST). Cancer Treat Rev. 2017;55 (1):107-19.

  3. Judson I, Bulusu R, Seddon B, Dangoor A, Wong N, Mudan S. UK clinical practice guidelines for the management of gastrointestinal stromal tumours (GIST). Clin Sarcoma Res. 2017;7 (1):6.

  4. ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2014 Sep;25 Suppl 3:iii21-6.

  5. Prakash D, Siragusa L, Wajed S, Manzelli A. The mass effect of a slowly growing GIST. BMJ Case Rep. 2018 Mar 5;2018. pii: bcr-2017-222556.

  6. Scola D, Bahoura L, Copelan A, Shirkhoda A, Sokhandon F. Getting the GIST: a pictorial review of the various patterns of presentation of gastrointestinal stromal tumors on imaging. Abdom Radiol. 2017;42 (5):1350-64.

  7. Werewka-Maczuga A, Stepien M, Urbanik A. Evaluation of Alterations in Tumor Tissue of Gastrointestinal Stromal Tumor (GIST) in Computed Tomography Following Treatment with Imatinib. Pol J Radiol. 2017;82(1):817-26.

  8. Lefebvre G, Cornelis F, Cumsille P, Colin T, Poignard C, Saut O. Spatial modelling of tumour drug resistance: the case of GIST liver metastases.Math Med Biol. 2017; 4 (2):151-76.

  9. Wasielewski K, Wasag B, Wozniak A, Pikiel J, Kowalik A, Osuch C, et al. Influence of Cytochrome P450, ABC and SLC Gene Polymorphisms on Imatinib Therapy Outcome of Patients with Gastrointestinal Stromal Tumours (GIST). Folia Biol (Praha). 2017;63(2):78-83.

  10. Rutkowski P, Bylina E, Lugowska I, Teterycz P, Klimczak A, Streb J, et al. Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST). J Geriatr Oncol. 2018;9(5):520-5.

  11. Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295-302.

  12. Son MK, Ryu MH, Park JO, Im SA, Kim TY, Lee SJ, et al. Efficacy and Safety of Regorafenib in Korean Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib: A Multicenter Study Based on the Management Access Program. Cancer Res Treat. 2017;49(2):350-7.

  13. Tamoschus D, Draexler K, Chang J, Ngai C, Madin- Warburton M, Pitcher A. Cost-Effectiveness Analysis of Regorafenib for Gastrointestinal Stromal Tumour (GIST) in Germany. Clin Drug Investig. 2017;37(6):525-33.

  14. Zhang Z, Jiang T, Wang W, Piao D. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumor after failure with imatinib and sunitinib treatment: A metaanalysis. Medicine (Baltimore). 2017;96 (48):e8698.

  15. Van Weehaeghe D, Gheysens O, Vandecaveye V, Schoffski P, Van Laere K, Deroose CM. Mixed response on regorafenib treatment for GIST (gastro-intestinal stromal tumor) according to (18)F-FDG-PET/CT. BMC Cancer. 2018;18(1):253.

  16. Wiegmann AL, Fair BA, Myers JA. Laparoscopic, Trans- Gastric Endoscopic Removal of Gastroesophageal Junction Gastrointestinal Stromal Tumors (GIST). Am Surg. 2017;83(7):234-7.

  17. Tanaka Y, Kosuga T, Komatsu S, Okamoto K, Shoda K, Arita T, et al. [Laparoscopic Local Resection for a Gastric GIST with Ulcer Locating Near to the Esophagogastric Junction - A Case Report]. [Article in Japanese] Gan To Kagaku Ryoho. 2017;44(12):1308-10.

  18. Reimondez S, Moser F, Maldonado PS, Alcaraz A, Rossini AM, Obeide LR. Gastrectomía atípica laparoscópica en el tratamiento de gist gástrico. Resultados a corto y mediano plazo. Med. 2017;77(4): 274-8.

  19. Somu K, Dashore AR, Shah AR, Anandh R. Laparoscopic excision of large lower rectal gastrointestinal stromal tumour (GIST): A case report. J Minim Access Surg. 2016;12(3):283-5.

  20. Loureiro Mde P, Almeida RA, Claus CM, Bonin EA, Cury- Filho AM, Dimbarre D, et al. Laparoscopic Resection of Gastrointestinal Stromal Tumors (Gist). Arq Bras Cir Dig. 2016;29(1):1-4.

  21. Hsiao CY, Yang CY, Lai IR, Chen CN, Lin MT. Laparoscopic resection for large gastric gastrointestinal stromal tumor (GIST): intermediate follow-up results. Surg Endosc. 2015;29(4):868-73.

  22. Tang S, Yin Y, Shen C, Chen J, Yin X, Zhang B, et al. Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST). World J Surg Oncol. 2017;15(1):79.

  23. Shi YN, Li Y, Wang LP, Wang ZH, Liang XB, Liang H, et al. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in North China. Medicine (Baltimore). 2017;96(46):e8240.

  24. Weldon CB, Madenci AL, Boikos SA, Janeway KA, George S, von Mehren M, et al. Surgical Management of Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Pediatric and Wildtype GIST Clinic. J Clin Oncol. 2017;35(5):523-8.

  25. Cianci P, Luini C, Marinoni M, Nespoli L, Salvatoni A, Salvatore S. Pediatric GIST presenting as anemia. Pediatr Hematol Oncol. 2017;34(5):343-7.




2020     |     www.medigraphic.com